Manages symptom complex of tension (or muscle contraction) headache. ANDA 75231, held by Lgm Pharma. Aspirin; Butalbital; Caffeine; Codeine Phosphate.
As of Nov 15, 2026, ANDA 75231 (Butalbital, Aspirin, Caffeine, And Codeine Phosphate), held by Lgm Pharma, was first approved by FDA on Nov 30, 2001, with 13 approved supplements and 0 published complete response letters.
Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP is indicated for the management of the symptom complex of tension (or muscle contraction) headache, when non-opioid analgesic and alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 30, 2001 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Butalbital, Aspirin, Caffeine, And Codeine Phosphate325MG;50MG;40MG;30MG · capsule;oral | Aspirin; Butalbital; Caffeine; Codeine Phosphate | Rx |
| Jun 18, 2026 | Supplement 16REMS | Approved | None posted |
| Dec 22, 2025 | Supplement 14Labeling · Standard review | Approved | None posted |
| May 9, 2025 | Supplement 13Labeling · Standard review | Approved | None posted |
| Oct 31, 2024 | Supplement 12REMS | Approved | None posted |
| Feb 12, 2024 | Supplement 11Labeling · Standard review | Approved | None posted |
| Feb 12, 2024 | Supplement 10Labeling · Standard review | Approved | None posted |
| Feb 12, 2024 | Supplement 9Labeling · Standard review | Approved | None posted |
| Feb 12, 2024 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 18, 2018 | Supplement 8REMS | Approved | None posted |
| Nov 20, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Dec 17, 2002 | Supplement 2Labeling | Approved | None posted |
| Dec 17, 2002 | Supplement 1Manufacturing | Approved | None posted |
| Aug 20, 2002 | Supplement 3Manufacturing | Approved | None posted |
| Nov 30, 2001 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters